Figure 2.

Activity of CBD and CBD‐DMH at CB₁ receptors in the presence of CP55,940. cAMP inhibition (A–C) was quantified relative to CP55,940 E _max (100%) in HEK‐CRE cells expressing CB₁ receptor‐GFP² treated with 1 nM–10 μM CP55,940 ± 1 nM–10 μM CBD (A) or CBD‐DMH (B), or CBD or CBD‐DMH alone (C), for 4 h. βarrestin1 recruitment (D–F) was measured via BRET² in HEK293A cells expressing CB₁ receptor‐GFP² and βarrestin1‐Rluc treated with 1 nM–10 μM CP55940 ± 1 nM–10 μM CBD (D) or CBD‐DMH (E), or CBD or CBD‐DMH alone (F), for 30 min. Data were fit with the allosteric operational model [A (R ² = 0.88), B (R ² = 0.97), D (R ² = 0.94), E (R ² = 0.82)] or dose–response with variable slope (C, F). Data are mean ± SEM; n = 6 independent experiments.